文献速递产科母胎医学

产前类固醇治疗无反应的复杂挑战

The complex challenge of antenatal steroid therapy nonresponsiveness.
PubMed 文献 · Am J Obstet Gynecol · 2022-08-03

产前类固醇治疗是早产临产妇女的标准护理,可降低新生儿死亡和呼吸窘迫综合征风险,但疗效存在显著变异,部分胎儿反应不足。本文综述临床和动物研究,定义无反应为治疗后死亡或诊断呼吸窘迫综合征,并探讨其机制及优化方向。

要点

  • 产前类固醇治疗可降低早产儿死亡和呼吸窘迫综合征风险,但存在显著反应变异。
  • 无反应定义为治疗后死亡或诊断呼吸窘迫综合征。
  • 24至35周分娩预防1例呼吸窘迫综合征需治疗19例(95%CI 14-28)。

核心结论

  • 产前类固醇治疗无反应现象显著,其变异可能源于治疗方案和个体因素,需优化应用并进一步研究。

研究设计与样本

  • 综述临床和动物研究,分析产前类固醇治疗反应变异及机制。

主要发现

  • 24至35周分娩预防1例呼吸窘迫综合征的需治疗人数为19(95%CI 14-28)。
  • >34周分娩需治疗人数为55(95%CI 30-304)。
  • 足月择期手术分娩需治疗人数为106(95%CI 61-421)。

关键数值与推荐

  • 无反应定义为治疗后死亡或诊断呼吸窘迫综合征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antenatal steroid therapy is standard care for women at imminent risk of preterm delivery. When deliveries occur within 7 days of treatment, antenatal steroid therapy reduces the risk of neonatal death and improves preterm outcomes by exerting diverse developmental effects on the fetal organs, in particular the preterm lung and cardiovascular system. There is, however, sizable variability in antenatal steroid treatment efficacy, and an important percentage of fetuses exposed to antenatal steroid therapy do not respond sufficiently to derive benefit. Respiratory distress syndrome, for example, is a central metric of clinical trials to assess antenatal steroid outcomes. In the present analysis, we addressed the concept of antenatal steroid nonresponsiveness, and defined a failed or suboptimal response to antenatal steroids as death or a diagnosis of respiratory distress syndrome following treatment. For deliveries at 24 to 35 weeks' gestation, the number needed to treat to prevent 1 case of respiratory distress syndrome was 19 (95% confidence interval, 14-28). Reflecting gestation-dependent risk, for deliveries at >34 weeks' gestation the number needed to treat was 55 (95% confidence interval, 30-304), whereas for elective surgical deliveries at term this number was 106 (95% confidence interval, 61-421). We reviewed data from clinical and animal studies investigating antenatal steroid therapy to highlight the significant incidence of antenatal steroid therapy nonresponsiveness (ie, residual mortality or respiratory distress syndrome after treatment), and the potential mechanisms underpinning this outcome variability. The origins of this variability may be related to both the manner in which the therapy is applied (ie, the treatment regimen itself) and factors specific to the individual (ie, genetic variation, stress, infection). The primary aims of this review were: (1) to emphasize to the obstetrical and neonatal communities the extent of antenatal steroid response variability and its potential impact; (2) to propose approaches by which antenatal steroid therapy may be better applied to improve overall benefit; and (3) to stimulate further research toward the empirical optimization of this important antenatal therapy.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Takahashi T, Jobe AH, Fee EL, et al. The complex challenge of antenatal steroid therapy nonresponsiveness. Am J Obstet Gynecol. 2022. PMID: 35932879. doi:10.1016/j.ajog.2022.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。